Novartis Venture Fund
Investment Details
Investor Type
Corporate VC
Asset Class Focus
Venture Capital
Stage Focus
Seed, Series A, Series B, Series C, Growth, Late Stage, Pre-IPO
Geographical Focus
United States, United Kingdom, Canada, Germany, Japan, China, France, Italy, Denmark, Switzerland, Spain, Luxembourg, South Korea, Ireland, Austria, Netherlands, Hungary, Portugal, Sweden, Belgium, Israel, Norway, Finland, Poland, Czech Republic
Industries Focus
- Healthcare
- Life Sciences
- Healthcare Services
- Digital Health
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Biotechnology
- Synthetic Biology
- Regenerative Medicine
- Oncology
- Neurology
- Infectious Diseases
- Consumer Health
- Vaccines
- Immunology
- Genomics
- Clinical Research
- Immuno-Oncology
- Rare Diseases
- Healthcare IT
- Cardiovascular
- Ophthalmology
- Respiratory
- Advanced Materials
- Cell Therapy
- Gene Therapy
- Medical Imaging
- Medical Robotics
- Dermatology
- Artificial Intelligence in Healthcare
- Metabolic Diseases
Investment Size:
5,000,000 to 25,000,000 USD
Investor Details Founded: 1996
The Novartis Venture Fund is the corporate venture capital arm of Novartis, focusing on early-stage life sciences companies worldwide. With approximately USD 750 million under management, the fund invests in biotechnology and biopharmaceutical companies, aiming to develop novel therapeutics and platforms that address unmet patient needs across the healthcare spectrum. The fund's investment strategy includes equity investments ranging from USD 5 million to USD 25 million, primarily in Seed and Series A stages, with flexibility to explore later-stage opportunities. The Novartis Venture Fund has a global presence, with offices in Basel, Switzerland, and Cambridge, Massachusetts, and has invested in over 40 life science companies across North America and Europe. The fund's portfolio spans various therapeutic areas, including oncology, immunology, neuroscience, and cardiovascular medicine, reflecting its commitment to advancing healthcare innovation. The team comprises professionals with strong backgrounds in life sciences and business development, enabling them to provide strategic support to portfolio companies. The fund's approach emphasizes active involvement, often taking seats on company boards to guide the development of transformative healthcare solutions. Through its investments, the Novartis Venture Fund aims to foster innovation and bring forward new therapeutic options for patients worldwide.
The Novartis Venture Fund's investment philosophy is centered on identifying and supporting companies with exceptional potential to drive innovation in the life sciences sector. By leveraging Novartis' extensive R&D infrastructure, regulatory expertise, and global commercialization capabilities, the fund provides portfolio companies with a comprehensive ecosystem to accelerate healthcare innovation. This collaborative approach enhances the development of groundbreaking products and solutions that address critical medical needs. The fund's strategic focus on early to mid-stage companies allows it to play a pivotal role in shaping the future of healthcare by nurturing ventures that are poised to make significant clinical impacts. Through its investments, the Novartis Venture Fund contributes to the advancement of solutions and fosters innovation within the life science sector.
In summary, the Novartis Venture Fund is a dynamic and active investor dedicated to advancing healthcare through strategic investments in early-stage life sciences companies. Its global reach, substantial capital resources, and commitment to innovation make it a key player in the venture capital landscape, driving the development of novel therapeutics and platforms that have the potential to transform patient care and improve health outcomes worldwide.
Requirements
- Innovative therapeutics and platforms addressing unmet patient needs
- Early-stage life sciences companies
- Global focus with emphasis on North America and Europe
- Active collaboration with portfolio companies to deliver clinical impact
- Companies developing novel therapeutics and platforms
- Early to mid-stage life sciences companies
- Global presence with a focus on North America and Europe
- Active involvement in company boards
- Alignment with Novartis' therapeutic areas including oncology, immunology, neuroscience, and cardiovascular medicine
Contact
[Official Website Hidden]
[HQ Location Hidden]
[Email Hidden]
[Contact Number Hidden]
Portfolio Companies
- Adimab
- Alnylam Pharmaceuticals
- Arctos Medical
- Cadent Therapeutics
- Chinook Therapeutics
- Gyroscope Therapeutics
- Kymab
- Molecular Partners
- MorphoSys AG
- Regulus Therapeutics
- Tornado Therapeutics
- Borealis Biosciences
- Versant Ventures
- AveXis
- BioNano Genomics
- Health Ever Biotech
- KisoJi
Mentioned In
-
$24.95
-
$14.95
-
$19.95
-
$39.95
-
$19.95
-
$19.95
-
$24.95
-
$99.00
-
$299.00
Claim this Investor
Are you an official representative of Novartis Venture Fund?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim